Literature DB >> 9328835

Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein.

T W Reichman1, J Albanell, X Wang, M A Moore, G P Studzinski.   

Abstract

Telomerase activity provides a mechanism for the unlimited division potential of neoplastic cells. Induced differentiation of these cells was found to be associated with repression of telomerase activity irrespective of the inducing agent. We have employed a series of sublines of human promyelocytic leukemia line HL60 with differing degrees of resistance to differentiation to determine how tightly the expression of the differentiated phenotype is coupled to the downregulation of telomerase activity and to the expression of the recently identified telomerase-associated protein 1 (TP1). As expected, in the 1,25D3-dihydroxyvitamin D3 (1,25D3)-resistant subclones (20A-100A cells), telomerase activity was not significantly downregulated by 1,25D3 and, in most cases, by all-trans retinoic acid (atRA), to which these cells were cross-resistant, but telomerase activity was repressed by dimethylsulfoxide (DMSO) and phorbol-12-myristate-13-acetate (TPA), to which the sublines were in general sensitive. However, there were exceptions; in some instances telomerase activity was repressed in the absence of the expression of markers of differentiation. Also, there was an inverse relationship between telomerase activity and the cellular levels of TP1 transcripts. We conclude that in HL60 cells downregulation of telomerase is loosely associated with upregulation of differentiation markers and with other cellular changes which include an upregulation of TP1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328835

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide.

Authors:  T J Moriarty; S Dupuis; C Autexier
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

2.  Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents.

Authors:  Z Lin; S Lim; M A Viani; M Sapp; M S Lim
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells.

Authors:  William K Love; J Tyson Deangelis; Joel B Berletch; Sharla Mo Phipps; Lucy G Andrews; Wayne J Brouillette; Donald D Muccio; Trygve O Tollefsbol
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

4.  Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663.

Authors:  Pan Jian; Zhao Wen Li; Tao Yan Fang; Wang Jian; Zhou Zhuan; Liao Xin Mei; Wu Shui Yan; Ni Jian
Journal:  J Hematol Oncol       Date:  2011-04-25       Impact factor: 17.388

5.  Autocrine stimulation of human pancreatic duct-like development by soluble isoforms of epimorphin in vitro.

Authors:  L Lehnert; M M Lerch; Y Hirai; M L Kruse; W Schmiegel; H Kalthoff
Journal:  J Cell Biol       Date:  2001-03-05       Impact factor: 10.539

6.  Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms.

Authors:  D Xu; A Gruber; M Björkholm; C Peterson; P Pisa
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

7.  Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma.

Authors:  N Toshikuni; K Nouso; T Higashi; H Nakatsukasa; T Onishi; T Kaneyoshi; Y Kobayashi; K Kariyama; K Yamamoto; T Tsuji
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.